Status
Conditions
Treatments
About
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM arm of the LEADERS trial.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Diana Schuette; Abderrahim Kadri
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal